Dolutegravir potentiates platelet activation by a calcium-dependent, ionophore-like mechanism
Dolutegravir is a highly potent HIV integrase strand transfer inhibitor that is recommended for first-line anti-retroviral treatment in all major treatment guidelines. A recent study has shown that people taking this class of anti-retroviral treatment have a substantially higher risk of early-onset...
Main Authors: | Morris Madzime, Annette J. Theron, Ronald Anderson, Gregory R. Tintinger, Helen C. Steel, Pieter W. A. Meyer, Jan G. Nel, Charles Feldman, Theresa M. Rossouw |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2022-12-01
|
Series: | Journal of Immunotoxicology |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/1547691X.2022.2142705 |
Similar Items
-
Clofazimine, but Not Isoniazid or Rifampicin, Augments Platelet Activation in vitro
by: Ronald Anderson, et al.
Published: (2018-11-01) -
Pro-Tumorigenic and Thrombotic Activities of Platelets in Lung Cancer
by: Ronald Anderson, et al.
Published: (2023-07-01) -
Pro-Inflammatory Interactions of Dolutegravir with Human Neutrophils in an In Vitro Study
by: Annette J. Theron, et al.
Published: (2022-12-01) -
Distribution and quantification of activated platelets in platelet-rich fibrin matrices
by: Atsushi Sato, et al.
Published: (2022-01-01) -
Platelet–Neutrophil Interaction and Thromboinflammation in Diabetes: Considerations for Novel Therapeutic Approaches
by: Julia S. Gauer, et al.
Published: (2022-10-01)